Creating a Beacon During a Time of Uncertainty for the Biotech Community
Altitude Lab, in collaboration with Chris Gibson and David Bearss, has launched the Altitude Lab Fund, a pre-seed fund aimed at supporting SBIR-awarded startups facing federal funding uncertainty. The fund underscores the crucial role of SBIR grants in translating academic discoveries into commercial success, as seen with companies like Fluidigm and Recursion. With recent cuts threatening U.S. leadership in biotech innovation, the fund will provide $100,000–$250,000 in pre-seed capital, lab space, and accelerator support to ensure promising health startups continue to thrive.